Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 2/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.32 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 3/20 | 0.31 |
| ▸ | TDO2 | P48775 | 2/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12720461 | 1.00 | SPR (0.39) | SPREGLN1KDM4CALDH1A1KDM4E | |
| SCHEMBL1625775 | 0.91 | EGLN1 (0.47) | SPREGLN1KDM4CALDH1A1 | |
| SCHEMBL1628261 | 0.91 | EGLN1 (0.47) | SPREGLN1KDM4CALDH1A1 | |
| SCHEMBL1626685 | 0.89 | MEN1 (0.42) | SPREGLN1ALDH1A1GAAP2RX1 | |
| SCHEMBL1627075 | 0.85 | MAPT (0.43) | SPREGLN1ALDH1A1KDM4EGAA | |
| SCHEMBL1625804 | 0.83 | SPR (0.43) | SPRALDH1A1KDM4EGAAPKM | |
| SCHEMBL12720446 | 0.82 | SPR (0.44) | SPREGLN1ALDH1A1KDM4EGAA | |
| SCHEMBL12720449 | 0.82 | SPR (0.44) | SPREGLN1ALDH1A1KDM4EGAA | |
| SCHEMBL12720376 | 0.80 | SPR (0.44) | SPREGLN1ALDH1A1KDM4EPKM | |
| SCHEMBL12720440 | 0.79 | EGLN1 (0.38) | SPREGLN1ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7635715-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | EGLN2, EGLN3, HIF1AN | SPR 754/4885EGLN1 4/4885KDM4C 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.